Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointm...

Related Keywords

Berkeley ,California ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Singapore ,Taiwan ,Adicet Bio ,Jay Backstrom ,Mo Qatanani ,Amir Nashat ,Molly Macleod ,Synageva Biopharma ,Rushmie Nofsinger ,David Hallal ,Twitter ,Baylor College Of Medicine ,Institute For Diabetes ,University Of California ,University Of Pennsylvania School Medicine ,Exchange Commission ,California Life Sciences ,Roche Holding ,American University Of Beirut ,Scholar Rock Inc ,Head Of Research At Dyne Therapeutics ,Kelley School Of Business ,Genentech ,Amgen Inc ,Allergan ,Linkedin ,Indiana University ,Alexion Pharmaceuticals ,Scholar Rock ,Katie Peng ,Chief Scientific ,Chief Commercial Officer ,General Manager ,Asia Pacific ,Kelley School ,Chief Executive Officer ,Dyne Therapeutics ,Human Genetics ,Baylor College ,Pennsylvania School ,American University ,Securities Act ,Private Securities Litigation Reform Act ,Quarterly Report ,